A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

Clinical trial NCT06940739 · RECRUITING

Trial details

NCT number: NCT06940739
Sponsor: Iovance Biotherapeutics, Inc.
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Unresectable Melanoma Metastatic Melanoma Ocular Melanoma

Start date: 2025-03-11
Primary completion: 2032-06-01
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.